Conduit Pharmaceuticals Inc. announced significant corporate changes in a recent Form 8-K filing with the SEC. On November 14, 2024, Simon Fry was appointed as a director of the company, effective December 18, 2024, after the annual meeting of stockholders. Fry brings over 35 years of investment banking experience to his new roles on the Audit and Compensation Committees. His initial compensation includes a stock option to purchase 420,000 shares of common stock. Additionally, on November 15, 2024, an amended employment agreement was executed with James Bligh, who will continue as the Interim Chief Financial Officer and Senior Vice President – Strategy. Bligh's agreement includes a £400,000 annual salary and up to a 40% discretionary cash bonus. The company also adopted an amendment to its bylaws, effective post the 2024 annual meeting, changing the quorum requirement for stockholder meetings from a majority to at least one-third of the voting power.

Conduit Pharmaceuticals Inc. announced significant corporate changes in a recent Form 8-K filing with the SEC. On November 14, 2024, Simon Fry was appointed as a director of the company, effective December 18, 2024, after the annual meeting of stockholders. Fry brings over 35 years of investment banking experience to his new roles on the Audit and Compensation Committees. His initial compensation includes a stock option to purchase 420,000 shares of common stock. Additionally, on November 15, 2024, an amended employment agreement was executed with James Bligh, who will continue as the Interim Chief Financial Officer and Senior Vice President – Strategy. Bligh's agreement includes a £400,000 annual salary and up to a 40% discretionary cash bonus. The company also adopted an amendment to its bylaws, effective post the 2024 annual meeting, changing the quorum requirement for stockholder meetings from a majority to at least one-third of the voting power.